Corcept Therapeutics
CORT
119.60
+0.03
+0.03%
Corcept Therapeutics
US · CORT
#1285 by market cap
Listed 1970
119.60
+0.03
+0.03%
Live - 5344 symbols - heartbeat 107s ago
· 2026-10-08 06:36
Pre-market
120.67
+0.89%
After-hours
119.60
0.00%
- Market cap
- 12.93B
- P/E (TTM)i
- 265.78
- P/Bi
- 18.32
- EPSi
- 0.82
- Div yieldi
- 0.00%
- 52W posi
- 93%
Reader sentiment
Are you bullish or bearish on CORT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 76.73% -0.01pp
- Institutions
- 487
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund60.97%
Individual/Insider10.68%
Hedge Fund10.07%
Public Company1.67%
Government Pension Fund1.35%
VC/PE Fund1.08%
Private Company0.75%
Sovereign Wealth Fund0.45%
Insurance Company0.21%
Other12.76%
Top holders
BlackRock
11.50%
Ingalls & Snyder, LLC
7.34%
George Baker
5.13%
Renaissance Technologies Corp.
4.87%
Vanguard Portfolio Management, LLC
4.67%
Vanguard Capital Management, LLC
4.43%
Parallel Advisors, LLC
3.67%
FMR
3.09%
State Street Global Advisors
3.03%
Joseph Belanoff
2.65%
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 9 buys · 39 sells
| Name | Role | Stake |
|---|---|---|
| George Baker | Independent Director | 5.13% |
| Joseph Belanoff | Chief Executive Officer | 2.65% |
| James Wilson | Independent Chairperson | 1.35% |
| David Mahoney | Independent Director | 1.07% |
| Hazel Hunt | Chief Scientific Officer | 0.24% |
| Sean Maduck | President of Corcept Endocrinology | 0.11% |
| Gary Robb | Chief Business Officer & Secretary | 0.09% |
| Atabak Mokari | Chief Financial Officer | 0.02% |
| Joseph Lyon | Chief Accounting Officer | 0.01% |
| William Guyer | Chief Development Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Joseph Lyon | Chief Accounting Officer | Derivative Exercise and Sale | -10,000 | $13.56–116.54 |
| 2026-10-01 | Roberto Vieira | President of Oncology | Derivative Exercise and Sale | -8,333 | $21.63–116.59 |
| 2026-09-30 | Joseph Lyon | Chief Accounting Officer | Intent to Sell (Form 144) | -10,000 | $115.23 |
| 2026-09-23 | Gary Robb | Chief Business Officer & Secretary | Other Acquisition | +10,000 | -- |
| 2026-09-23 | Gary Robb | Chief Business Officer & Secretary | Other Disposition | -17,100 | -- |
| 2026-09-16 | Gary Robb | Chief Business Officer & Secretary | Derivative Exercise and Retained | +17,493 | $8.27 |
| 2026-09-15 | Roberto Vieira | President of Oncology | Automatic Disposition | -296 | $100.82 |
| 2026-09-14 | James Wilson | Independent Chairperson | Automatic Disposition | -10,000 | $110.27–111.70 |
| 2026-09-13 | Joseph Lyon | Chief Accounting Officer | Derivative Exercise and Sale | -10,000 | $11.35–114.12 |
| 2026-09-01 | Atabak Mokari | Chief Financial Officer | Sale to Issuer | -102 | $113.38 |
| 2026-09-01 | Gary Robb | Chief Business Officer & Secretary | Sale to Issuer | -91 | $113.38 |
| 2026-09-01 | Sean Maduck | President of Corcept Endocrinology | Sale to Issuer | -117 | $113.38 |
| 2026-09-01 | Joseph Lyon | Chief Accounting Officer | Sale to Issuer | -72 | $113.38 |
| 2026-09-01 | Roberto Vieira | President of Oncology | Sale to Issuer | -102 | $113.38 |
| 2026-09-01 | Roberto Vieira | President of Oncology | Derivative Exercise and Sale | -58,333 | $21.63–115.44 |
| 2026-08-31 | Atabak Mokari | Chief Financial Officer | Other Acquisition | +276 | $113.38 |
| 2026-08-31 | Gary Robb | Chief Business Officer & Secretary | Other Acquisition | +328 | $113.38 |
| 2026-08-31 | Sean Maduck | President of Corcept Endocrinology | Other Acquisition | +300 | $113.38 |
| 2026-08-31 | Sean Maduck | President of Corcept Endocrinology | Derivative Exercise and Sale | -25,000 | $8.27–115.61 |
| 2026-08-31 | Joseph Lyon | Chief Accounting Officer | Other Acquisition | +260 | $113.38 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:36:38 · For reference only, not investment advice and not tailored to your situation.